Pyrazolopyrimidine A2a Antagonists With Selective Oral Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders and cancers targeting the A2a receptor suffer from non-selectivity and adverse side effects, particularly due to the lack of specificity towards the A1 receptor, and face challenges with aqueous solubility for oral administration.
Innovation Solution
Development of pyrazolo[3,4-d]pyrimidine core compounds with a 4-amino-2H-pyrazolo[3,4-d]pyrimidine structure, featuring a 5- or 6-membered aromatic heterocycle at the 6-position and a phenyl or heterocycle attached via a CH2 linker, which act as selective A2a receptor antagonists, offering improved selectivity over A1, A2b, and A3 receptors, and possess favorable pharmacokinetic properties and aqueous solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing A2a receptor antagonists are used, then anti-tumour activity is achieved, but non-selectivity towards A1 receptor causes adverse side effects
Solution Approach 1:
The patent modifies molecular parameters of the receptor antagonist by introducing a pyrazolo[3,4-d]pyrimidine core structure with specific substituents at defined positions. This changes the chemical parameters to achieve high selectivity for A2a receptor over A1 receptor, thereby reducing adverse side effects while maintaining anti-tumour activity.
Solution Approach 2:
The invention creates a composite molecular structure combining a pyrazolo[3,4-d]pyrimidine core with specific side chains and substituents. This composite structure enables selective binding to A2a receptor, resolving the contradiction between achieving anti-tumour effect and avoiding adverse side effects from non-selectivity.
2Reliability
If existing A2a receptor antagonists are used, then neurological disorder treatment is achieved, but poor aqueous solubility limits oral administration
Solution Approach 1:
The patent modifies the solubility parameters of the compound by introducing hydrophilic substituents and functional groups at specific positions of the pyrazolo[3,4-d]pyrimidine core. This changes the physical-chemical parameters to improve aqueous solubility, enabling oral administration while maintaining therapeutic efficacy.
3Reliability
If selective A2a receptor antagonists are developed, then adverse side effects are reduced, but manufacturing complexity increases
Solution Approach 1:
The patent divides the molecular structure into distinct segments: a pyrazolo[3,4-d]pyrimidine core and separate substituent groups at defined positions. This segmentation allows independent optimization of each part, achieving high selectivity while simplifying the synthesis process by allowing modular assembly of components.
Data Source
AI summary
The invention provides a compound of formula (I), or pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate,wherein R1 is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered aromatic heterocycle; and R2 is an optionally substituted 5- or 6-membered aromatic heterocycle. Also provided are pharmaceutical compositions comprising a compound of formula (I).